These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

840 related articles for article (PubMed ID: 30045977)

  • 41. Inhibition of LRRK2 kinase activity promotes anterograde axonal transport and presynaptic targeting of α-synuclein.
    Brzozowski CF; Hijaz BA; Singh V; Gcwensa NZ; Kelly K; Boyden ES; West AB; Sarkar D; Volpicelli-Daley LA
    Acta Neuropathol Commun; 2021 Nov; 9(1):180. PubMed ID: 34749824
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway.
    Carballo-Carbajal I; Weber-Endress S; Rovelli G; Chan D; Wolozin B; Klein CL; Patenge N; Gasser T; Kahle PJ
    Cell Signal; 2010 May; 22(5):821-7. PubMed ID: 20074637
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pathogenic LRRK2 requires secondary factors to induce cellular toxicity.
    Lobbestael E; Van den Haute C; Macchi F; Taymans JM; Baekelandt V
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32975566
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease.
    Cresto N; Gardier C; Gubinelli F; Gaillard MC; Liot G; West AB; Brouillet E
    Eur J Neurosci; 2019 Feb; 49(3):339-363. PubMed ID: 30269383
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations.
    Sheng Z; Zhang S; Bustos D; Kleinheinz T; Le Pichon CE; Dominguez SL; Solanoy HO; Drummond J; Zhang X; Ding X; Cai F; Song Q; Li X; Yue Z; van der Brug MP; Burdick DJ; Gunzner-Toste J; Chen H; Liu X; Estrada AA; Sweeney ZK; Scearce-Levie K; Moffat JG; Kirkpatrick DS; Zhu H
    Sci Transl Med; 2012 Dec; 4(164):164ra161. PubMed ID: 23241745
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.
    Daher JP; Abdelmotilib HA; Hu X; Volpicelli-Daley LA; Moehle MS; Fraser KB; Needle E; Chen Y; Steyn SJ; Galatsis P; Hirst WD; West AB
    J Biol Chem; 2015 Aug; 290(32):19433-44. PubMed ID: 26078453
    [TBL] [Abstract][Full Text] [Related]  

  • 47.
    Garrido A; Fairfoul G; Tolosa ES; Martí MJ; Green A;
    Ann Clin Transl Neurol; 2019 Jun; 6(6):1024-1032. PubMed ID: 31211166
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pathological Functions of LRRK2 in Parkinson's Disease.
    Jeong GR; Lee BD
    Cells; 2020 Nov; 9(12):. PubMed ID: 33266247
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The LRRK2-macroautophagy axis and its relevance to Parkinson's disease.
    Manzoni C
    Biochem Soc Trans; 2017 Feb; 45(1):155-162. PubMed ID: 28202669
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease.
    Li X; Wang QJ; Pan N; Lee S; Zhao Y; Chait BT; Yue Z
    PLoS One; 2011 Mar; 6(3):e17153. PubMed ID: 21390248
    [TBL] [Abstract][Full Text] [Related]  

  • 51. P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances neuronal toxicity.
    Kalogeropulou AF; Zhao J; Bolliger MF; Memou A; Narasimha S; Molitor TP; Wilson WH; Rideout HJ; Nichols RJ
    Biochem J; 2018 Apr; 475(7):1271-1293. PubMed ID: 29519959
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cellular and subcellular localization of Rab10 and phospho-T73 Rab10 in the mouse and human brain.
    Singh V; Menard MA; Serrano GE; Beach TG; Zhao HT; Riley-DiPaolo A; Subrahmanian N; LaVoie MJ; Volpicelli-Daley LA
    Acta Neuropathol Commun; 2023 Dec; 11(1):201. PubMed ID: 38110990
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications.
    Qing H; Wong W; McGeer EG; McGeer PL
    Biochem Biophys Res Commun; 2009 Sep; 387(1):149-52. PubMed ID: 19576176
    [TBL] [Abstract][Full Text] [Related]  

  • 54. LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients.
    Atashrazm F; Hammond D; Perera G; Bolliger MF; Matar E; Halliday GM; Schüle B; Lewis SJG; Nichols RJ; Dzamko N
    Mov Disord; 2019 Mar; 34(3):406-415. PubMed ID: 30597610
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical characteristics and pathophysiological properties of newly discovered LRRK2 variants associated with Parkinson's disease.
    Tezuka T; Ishiguro M; Taniguchi D; Osogaguchi E; Shiba-Fukushima K; Ogata J; Ishii R; Ikeda A; Li Y; Yoshino H; Matsui T; Kaida K; Funayama M; Nishioka K; Kumazawa F; Matsubara T; Tsuda H; Saito Y; Murayama S; Imai Y; Hattori N
    Neurobiol Dis; 2024 Sep; 199():106571. PubMed ID: 38901781
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Physiological and pathological roles of LRRK2 in the nuclear envelope integrity.
    Shani V; Safory H; Szargel R; Wang N; Cohen T; Elghani FA; Hamza H; Savyon M; Radzishevsky I; Shaulov L; Rott R; Lim KL; Ross CA; Bandopadhyay R; Zhang H; Engelender S
    Hum Mol Genet; 2019 Dec; 28(23):3982-3996. PubMed ID: 31626293
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A leucine-rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls.
    Vissers MFJM; Troyer MD; Thijssen E; Pereira DR; Heuberger JAAC; Groeneveld GJ; Huntwork-Rodriguez S
    Clin Transl Sci; 2023 Aug; 16(8):1408-1420. PubMed ID: 37177855
    [TBL] [Abstract][Full Text] [Related]  

  • 58. LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson's disease.
    Nguyen M; Krainc D
    Proc Natl Acad Sci U S A; 2018 May; 115(21):5576-5581. PubMed ID: 29735704
    [TBL] [Abstract][Full Text] [Related]  

  • 59. LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson's disease.
    Rocha EM; De Miranda BR; Castro S; Drolet R; Hatcher NG; Yao L; Smith SM; Keeney MT; Di Maio R; Kofler J; Hastings TG; Greenamyre JT
    Neurobiol Dis; 2020 Feb; 134():104626. PubMed ID: 31618685
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology.
    Xiong Y; Neifert S; Karuppagounder SS; Stankowski JN; Lee BD; Grima JC; Chen G; Ko HS; Lee Y; Swing D; Tessarollo L; Dawson TM; Dawson VL
    eNeuro; 2017; 4(2):. PubMed ID: 28321439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.